Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

RIGL Rigel Pharmaceuticals Inc. (New)
$46.75 3.64% +1.64
Notify me if price changes either direction
Interactive Brokers Logotype

Buy RIGL stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 873.3M
Enterprise value 801.8M
Trailing PE 2.6802843
Forward PE 9.165526
PEG Ratio -0.0371889446625
Enterprise to EBITDA 8.939
Enterprise to revenue 2.897
Price to book MRQ 1.985004
Price to sales TTM 3.0552142

Financials

Fiscal Year Ends 2025-12-31
Most Recent Quarter (MRQ) 2026-06-30
Revenue (TTM) 276.8M
EBITDA 94.0M
Diluted EPS TTM 16.89
Total Cash (MRQ) 95.3M
Current ratio (MRQ) 1.941
Operating Cash Flow (TTM) 79.4M

RIGL trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent RIGL News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.